Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBM-BMX in metastatic uveal melanoma
NCT07136181Phase 2Recruiting
- Sponsor
- Novelwise Pharmaceutical Corporation
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NBM-BMX in uveal melanoma (UM), sponsored by Novelwise Pharmaceutical Corporation. Started Nov 2025; status: recruiting.
02
Drugs
NBM-BMX
03
Conditions
uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07136181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136181.